GSK reports positive Phase III results for depemokimab The Pharma LetterGSK reveals promising asthma drug results with 54% reduction in exacerbations Investing.com IndiaDepemokimab late-breaking data presented at ERS ShareCastGSK ultra-long-acting biologic shows Phase III potential European Pharmaceutical ReviewGSK’s long-acting asthma drug halved attacks in phase 3, backing up blockbuster hopes Fierce Biotech
Read More…
GSK reports positive Phase III results for depemokimab – The Pharma Letter
